BDC 3042
Alternative Names: BDC-3042Latest Information Update: 10 Jun 2025
At a glance
- Originator Bolt Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CLEC6A protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacokinetics and pharmacokinetics data from a phase-I/II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research(AACR-2025)
- 25 Apr 2025 Efficacy and adverse events data from a phase-I/II trial in Solid tumours released by Bolt Biotherapeutics
- 24 Mar 2025 Bolt Biotherapeutics completes enrolment of patients in phase I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06052852)